Abstract
Monoamine oxidase inhibitor and tricyclic antidepressants have been serendipitously used for the treatment of depression for more than half a century and subsequently found to promote monoaminergic signals in the brain. Antidepressant dugs are still clinically used and industrially designed on the basis of the monoaminergic theory. Recent developments regarding selective monoaminergic uptake inhibitors can further improve the safe and rational treatment for patients with depression. However, monoamine-based antidepressants may cause unfavorable and incomplete remission of a considerable number of patients with depression; therefore, development of new antidepressant drugs based on other mechanisms is required. Meanwhile, there has been an impressive accumulation of knowledge about cytokines that might contribute to the understanding of the pathophysiology of depression. Therefore, this review focuses on the association between depressive disorder and cytokines and discusses the strategies for developing new cytokine-based antidepressant drugs.
Keywords: Depressive disorder, antidepressant, cytokine, interleukin, interferon, sickness behavior
Current Pharmaceutical Design
Title: New Approaches to Antidepressant Drug Design: Cytokine-Regulated Pathways
Volume: 15 Issue: 14
Author(s): Akira Nishida, Tsuyoshi Miyaoka, Takuji Inagaki and Jun Horiguchi
Affiliation:
Keywords: Depressive disorder, antidepressant, cytokine, interleukin, interferon, sickness behavior
Abstract: Monoamine oxidase inhibitor and tricyclic antidepressants have been serendipitously used for the treatment of depression for more than half a century and subsequently found to promote monoaminergic signals in the brain. Antidepressant dugs are still clinically used and industrially designed on the basis of the monoaminergic theory. Recent developments regarding selective monoaminergic uptake inhibitors can further improve the safe and rational treatment for patients with depression. However, monoamine-based antidepressants may cause unfavorable and incomplete remission of a considerable number of patients with depression; therefore, development of new antidepressant drugs based on other mechanisms is required. Meanwhile, there has been an impressive accumulation of knowledge about cytokines that might contribute to the understanding of the pathophysiology of depression. Therefore, this review focuses on the association between depressive disorder and cytokines and discusses the strategies for developing new cytokine-based antidepressant drugs.
Export Options
About this article
Cite this article as:
Nishida Akira, Miyaoka Tsuyoshi, Inagaki Takuji and Horiguchi Jun, New Approaches to Antidepressant Drug Design: Cytokine-Regulated Pathways, Current Pharmaceutical Design 2009; 15 (14) . https://dx.doi.org/10.2174/138161209788168065
DOI https://dx.doi.org/10.2174/138161209788168065 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Levosimendan: A Novel Agent in Heart Failure
Recent Patents on Cardiovascular Drug Discovery Cognitive Dysfunction in Depression – Pathophysiology and Novel Targets
CNS & Neurological Disorders - Drug Targets The Relationship Between Inflammation, Dyslipidemia and Physical Exercise: From the Epidemiological to Molecular Approach
Current Diabetes Reviews Is Metabolic Syndrome Associated to HIV Infection Per Se? Results from the HERMES Study
Current HIV Research Inflammation and Neurogenesis in Temporal Lobe Epilepsy
Current Drug Targets - CNS & Neurological Disorders Analysis of Proteins in Aerenchymatous Seminal Roots of Wheat Grown in Hypoxic Soils Under Waterlogged Conditions
Protein & Peptide Letters Nonviral Vectors for Cancer Gene Therapy: Prospects for Integrating Vectors and Combination Therapies
Current Gene Therapy The Genetic Regulation of ADPRT/PARP-1 in Aging and Cancer Susceptibility
Current Pharmacogenomics A Developmental Approach to Drug-induced Liver Injury in Newborns and Children
Current Medicinal Chemistry What is Known About the Antiviral Agents Active Against Bovine Viral Diarrhea Virus (BVDV)?
Current Medicinal Chemistry Adenosine Receptors: New Therapeutic Targets for Inflammation in Diabetic Nephropathy
Inflammation & Allergy - Drug Targets (Discontinued) Colchicine: An Old Wine in a New Bottle?
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry A Review of the Physiological Factors Associated with Alcohol Hangover
Current Drug Abuse Reviews Hepatocyte Growth Factor Signaling in Cancer Metastasis
Current Signal Transduction Therapy O-6-methylguanine-DNA Methyltransferase Inhibits Gastric Carcinoma Cell Migration and Invasion by Downregulation of Matrix Metalloproteinase 2
Anti-Cancer Agents in Medicinal Chemistry Searching for Artemisinin Production Improvement in Plants and Microorganisms
Current Pharmaceutical Biotechnology A Novel Approach to Refractory Epilepsy by Targeting Pgp Peripherally and Centrally: Therapeutic Targets and Future Perspectives
CNS & Neurological Disorders - Drug Targets Anti-Inflammatory and Antimicrobial Effects of Flavonoids from Heliotropium ellipticum Exudate
Current Bioactive Compounds Subject Index To Volume 2
Current Cardiology Reviews Editorial [Hot topic: Prion Diseases: Targets and Treatments of Symptoms and Disease Progression (Guest Editor: Brian Appleby)]
CNS & Neurological Disorders - Drug Targets